Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. mirchol

MiRCHOL SIGNED

Mechanistic and therapeutic implications of microRNA deregulation for drug resistance in bile duct cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MiRCHOL project word cloud

Explore the words cloud of the MiRCHOL project. It provides you a very rough idea of what is the project "MiRCHOL" about.

deregulation    tumor    crispr    editing    expert    pattern    gt    myself    cancers    emphasized    modulate    heterogeneity    chemoresistance    therapy    unclear    chemoresistant    supervise    complicating    genes    achievement    transferable    dismal    expertise    rate    disease    reflecting    expression    metastasis    world    clinical    instability    consequence    characterization    limited    mortality    options    doubled    besides    genome    involvement    micrornas    completion    orchestrating    drug    yield    efficacy    vast    stage    plus    deregulated    pathogenesis    transcriptomes    dr    70    liver    resistance    37    survival    matched    progression    integrate    last    unresectable    patients    regulate    diagnosis    hepatobiliary    andersen    translational    cancer    data    society    mir    outcome    patient    independent    ing    successful    cca    linking    molecular    urgently    scientific    me    skills    alone    5    multiple    hence    cholangiocarcinoma    medicine    researcher    mirs    incidence    treatment    insights    expand    genomic   

Project "MiRCHOL" data sheet

The following table provides information about the project.

Coordinator		 KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Denmark [DK]
 Total cost 200˙194 €
 EC max contribution 200˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-07-23

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 200˙194.00

Map

 Project objective

Cholangiocarcinoma (CCA) is a dismal type of liver cancer which incidence has more than doubled the last 20 years and mortality rate in Europe alone increased 37%, reflecting the limited treatment options. In >70% of patients CCA is unresectable due to advanced stage of disease at diagnosis, resulting in a 5% 5-year survival rate. CCA is characterized by molecular and clinical heterogeneity, complicating therapy and assessment of drug efficacy. Tumor heterogeneity is emphasized in limited response of therapy (drug resistance) and besides genomic instability a likely consequence of deregulated pathways under control of microRNAs (miRs). Each miR can regulate multiple genes/pathways, directly linking them to tumor heterogeneity. Deregulation of miRs can cause/control chemoresistance in other cancers, but in CCA their role is yet unclear. Thus, detailed characterization of miRs in CCA, focusing on their impact in drug resistance is urgently needed. Hence, I have 3 specific aims of this proposal: to 1) characterize the deregulated expression pattern of miRs involved in CCA pathogenesis and integrate this data with transcriptomes obtained from matched patients; 2) determine the role of deregulated miRs in control of chemoresistance, and 3) modulate by genome-editing key deregulated miR(s) targeting chemoresistant genes using the novel `CRISPR-Mir’ method. Achievement of these aims will yield key new insights into the role of miRs in orchestrating CCA progression and metastasis, as well as their involvement in drug resistance. My findings will have an impact on the society and in particular in patient outcome. Dr. Andersen, a world-wide expert in the molecular pathogenesis of CCA with a vast experience in genome medicine, will supervise the project. Successful completion of this proposal will enable me to expand my scientific expertise (plus technical and transferable skills) and to establish myself as an independent researcher in hepatobiliary and translational research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRCHOL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIRCHOL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

MNSWLGM (2019)

An optofluidic platform based on liquid-gradient refractive index microlens for the isolation and quantification of extracellular vesicles

Read More  

CODer (2020)

The molecular basis and genetic control of local gene co-expression and its impact in human disease

Read More